The ADC binds TROP-2 on tumor cells, is internalized, and releases SN-38, which inhibits DNA topoisomerase I to cause DNA damage and apoptosis. Topoisomerase I is the intracellular enzyme target of the payload, not the cell-surface antigen used for selective killing; cells expressing only topoisomerase I are not specifically targeted.